Selected research
Market Outlook & Growth Opportunities
Global Comprehensive Genomic Profiling Market Outlook and Growth Opportunities 2026
Market perspective
The global Comprehensive Genomic Profiling market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Comprehensive Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Comprehensive Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Comprehensive Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Comprehensive Genomic Profiling market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Comprehensive Genomic Profiling market include Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, QIAGEN and Agilent Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Comprehensive Genomic Profiling market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Comprehensive Genomic Profiling and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Comprehensive Genomic Profiling revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Comprehensive Genomic Profiling market.
Comprehensive Genomic Profiling Segment by Company
Tempus AI
Labcorp
NeoGenomics
Exact Sciences
Personalis
Illumina
Thermo Fisher Scientific
QIAGEN
Agilent Technologies
SOPHiA GENETICS
Sysmex
Burning Rock Biotech
Genetron Health
Geneseeq
BGI Genomics
Amoy Diagnostics
Roche
Guardant Health
Caris Life Sciences
Comprehensive Genomic Profiling Segment by Type
Tissue-based Profiling
Liquid Biopsy Profiling
Other
Comprehensive Genomic Profiling Segment by Application
Hospitals and Cancer Centers
Independent Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Other
Comprehensive Genomic Profiling Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Comprehensive Genomic Profiling status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Comprehensive Genomic Profiling key companies, revenue, market share, and recent developments.
3. To split the Comprehensive Genomic Profiling breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Comprehensive Genomic Profiling market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Comprehensive Genomic Profiling significant trends, drivers, influence factors in global and regions.
6. To analyze Comprehensive Genomic Profiling competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Comprehensive Genomic Profiling market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Comprehensive Genomic Profiling and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Comprehensive Genomic Profiling.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Comprehensive Genomic Profiling industry.
Chapter 3: Detailed analysis of Comprehensive Genomic Profiling company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Comprehensive Genomic Profiling in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Comprehensive Genomic Profiling in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Tissue-based Profiling
- Liquid Biopsy Profiling
- Other
Applications
- Hospitals and Cancer Centers
- Independent Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
- Other
Companies covered
- Tempus AI
- Labcorp
- NeoGenomics
- Exact Sciences
- Personalis
- Illumina
- Thermo Fisher Scientific
- QIAGEN
- Agilent Technologies
- SOPHiA GENETICS
- Sysmex
- Burning Rock Biotech
- Genetron Health
- Geneseeq
- BGI Genomics
- Amoy Diagnostics
- Roche
- Guardant Health
- Caris Life Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Comprehensive Genomic Profiling Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Comprehensive Genomic Profiling Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Comprehensive Genomic Profiling Market Dynamics
- 2.1 Comprehensive Genomic Profiling Industry Trends
- 2.2 Comprehensive Genomic Profiling Industry Drivers
- 2.3 Comprehensive Genomic Profiling Industry Opportunities and Challenges
- 2.4 Comprehensive Genomic Profiling Industry Restraints
3 Comprehensive Genomic Profiling Market by Company
- 3.1 Global Comprehensive Genomic Profiling Company Revenue Ranking in 2025
- 3.2 Global Comprehensive Genomic Profiling Revenue by Company (2021-2026)
- 3.3 Global Comprehensive Genomic Profiling Company Ranking (2024-2026)
- 3.4 Global Comprehensive Genomic Profiling Company Manufacturing Base and Headquarters
- 3.5 Global Comprehensive Genomic Profiling Company Product Type and Application
- 3.6 Global Comprehensive Genomic Profiling Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Comprehensive Genomic Profiling Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Comprehensive Genomic Profiling Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Comprehensive Genomic Profiling Market by Type
- 4.1 Comprehensive Genomic Profiling Type Introduction
- 4.1.1 Tissue-based Profiling
- 4.1.2 Liquid Biopsy Profiling
- 4.1.3 Other
- 4.2 Global Comprehensive Genomic Profiling Sales Value by Type
- 4.2.1 Global Comprehensive Genomic Profiling Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Comprehensive Genomic Profiling Sales Value by Type (2021-2032)
- 4.2.3 Global Comprehensive Genomic Profiling Sales Value Share by Type (2021-2032)
5 Comprehensive Genomic Profiling Market by Application
- 5.1 Comprehensive Genomic Profiling Application Introduction
- 5.1.1 Hospitals and Cancer Centers
- 5.1.2 Independent Clinical Laboratories
- 5.1.3 Pharmaceutical and Biotechnology Companies
- 5.1.4 Other
- 5.2 Global Comprehensive Genomic Profiling Sales Value by Application
- 5.2.1 Global Comprehensive Genomic Profiling Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Comprehensive Genomic Profiling Sales Value by Application (2021-2032)
- 5.2.3 Global Comprehensive Genomic Profiling Sales Value Share by Application (2021-2032)
6 Comprehensive Genomic Profiling Regional Value Analysis
- 6.1 Global Comprehensive Genomic Profiling Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Comprehensive Genomic Profiling Sales Value by Region (2021-2032)
- 6.2.1 Global Comprehensive Genomic Profiling Sales Value by Region: 2021-2026
- 6.2.2 Global Comprehensive Genomic Profiling Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Comprehensive Genomic Profiling Sales Value (2021-2032)
- 6.3.2 North America Comprehensive Genomic Profiling Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Comprehensive Genomic Profiling Sales Value (2021-2032)
- 6.4.2 Europe Comprehensive Genomic Profiling Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Comprehensive Genomic Profiling Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Comprehensive Genomic Profiling Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Comprehensive Genomic Profiling Sales Value (2021-2032)
- 6.6.2 South America Comprehensive Genomic Profiling Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Comprehensive Genomic Profiling Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Comprehensive Genomic Profiling Sales Value Share by Country, 2025 VS 2032
7 Comprehensive Genomic Profiling Country-level Value Analysis
- 7.1 Global Comprehensive Genomic Profiling Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Comprehensive Genomic Profiling Sales Value by Country (2021-2032)
- 7.2.1 Global Comprehensive Genomic Profiling Sales Value by Country (2021-2026)
- 7.2.2 Global Comprehensive Genomic Profiling Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.7.2 France Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.14.2 China Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.17.2 India Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Comprehensive Genomic Profiling Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Comprehensive Genomic Profiling Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Comprehensive Genomic Profiling Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Tempus AI
- 8.1.1 Tempus AI Company Information
- 8.1.2 Tempus AI Business Overview
- 8.1.3 Tempus AI Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.1.4 Tempus AI Comprehensive Genomic Profiling Product Portfolio
- 8.1.5 Tempus AI Recent Developments
- 8.2 Labcorp
- 8.2.1 Labcorp Company Information
- 8.2.2 Labcorp Business Overview
- 8.2.3 Labcorp Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.2.4 Labcorp Comprehensive Genomic Profiling Product Portfolio
- 8.2.5 Labcorp Recent Developments
- 8.3 NeoGenomics
- 8.3.1 NeoGenomics Company Information
- 8.3.2 NeoGenomics Business Overview
- 8.3.3 NeoGenomics Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.3.4 NeoGenomics Comprehensive Genomic Profiling Product Portfolio
- 8.3.5 NeoGenomics Recent Developments
- 8.4 Exact Sciences
- 8.4.1 Exact Sciences Company Information
- 8.4.2 Exact Sciences Business Overview
- 8.4.3 Exact Sciences Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.4.4 Exact Sciences Comprehensive Genomic Profiling Product Portfolio
- 8.4.5 Exact Sciences Recent Developments
- 8.5 Personalis
- 8.5.1 Personalis Company Information
- 8.5.2 Personalis Business Overview
- 8.5.3 Personalis Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.5.4 Personalis Comprehensive Genomic Profiling Product Portfolio
- 8.5.5 Personalis Recent Developments
- 8.6 Illumina
- 8.6.1 Illumina Company Information
- 8.6.2 Illumina Business Overview
- 8.6.3 Illumina Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.6.4 Illumina Comprehensive Genomic Profiling Product Portfolio
- 8.6.5 Illumina Recent Developments
- 8.7 Thermo Fisher Scientific
- 8.7.1 Thermo Fisher Scientific Company Information
- 8.7.2 Thermo Fisher Scientific Business Overview
- 8.7.3 Thermo Fisher Scientific Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.7.4 Thermo Fisher Scientific Comprehensive Genomic Profiling Product Portfolio
- 8.7.5 Thermo Fisher Scientific Recent Developments
- 8.8 QIAGEN
- 8.8.1 QIAGEN Company Information
- 8.8.2 QIAGEN Business Overview
- 8.8.3 QIAGEN Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.8.4 QIAGEN Comprehensive Genomic Profiling Product Portfolio
- 8.8.5 QIAGEN Recent Developments
- 8.9 Agilent Technologies
- 8.9.1 Agilent Technologies Company Information
- 8.9.2 Agilent Technologies Business Overview
- 8.9.3 Agilent Technologies Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.9.4 Agilent Technologies Comprehensive Genomic Profiling Product Portfolio
- 8.9.5 Agilent Technologies Recent Developments
- 8.10 SOPHiA GENETICS
- 8.10.1 SOPHiA GENETICS Company Information
- 8.10.2 SOPHiA GENETICS Business Overview
- 8.10.3 SOPHiA GENETICS Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.10.4 SOPHiA GENETICS Comprehensive Genomic Profiling Product Portfolio
- 8.10.5 SOPHiA GENETICS Recent Developments
- 8.11 Sysmex
- 8.11.1 Sysmex Company Information
- 8.11.2 Sysmex Business Overview
- 8.11.3 Sysmex Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.11.4 Sysmex Comprehensive Genomic Profiling Product Portfolio
- 8.11.5 Sysmex Recent Developments
- 8.12 Burning Rock Biotech
- 8.12.1 Burning Rock Biotech Company Information
- 8.12.2 Burning Rock Biotech Business Overview
- 8.12.3 Burning Rock Biotech Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.12.4 Burning Rock Biotech Comprehensive Genomic Profiling Product Portfolio
- 8.12.5 Burning Rock Biotech Recent Developments
- 8.13 Genetron Health
- 8.13.1 Genetron Health Company Information
- 8.13.2 Genetron Health Business Overview
- 8.13.3 Genetron Health Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.13.4 Genetron Health Comprehensive Genomic Profiling Product Portfolio
- 8.13.5 Genetron Health Recent Developments
- 8.14 Geneseeq
- 8.14.1 Geneseeq Company Information
- 8.14.2 Geneseeq Business Overview
- 8.14.3 Geneseeq Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.14.4 Geneseeq Comprehensive Genomic Profiling Product Portfolio
- 8.14.5 Geneseeq Recent Developments
- 8.15 BGI Genomics
- 8.15.1 BGI Genomics Company Information
- 8.15.2 BGI Genomics Business Overview
- 8.15.3 BGI Genomics Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.15.4 BGI Genomics Comprehensive Genomic Profiling Product Portfolio
- 8.15.5 BGI Genomics Recent Developments
- 8.16 Amoy Diagnostics
- 8.16.1 Amoy Diagnostics Company Information
- 8.16.2 Amoy Diagnostics Business Overview
- 8.16.3 Amoy Diagnostics Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.16.4 Amoy Diagnostics Comprehensive Genomic Profiling Product Portfolio
- 8.16.5 Amoy Diagnostics Recent Developments
- 8.17 Roche
- 8.17.1 Roche Company Information
- 8.17.2 Roche Business Overview
- 8.17.3 Roche Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.17.4 Roche Comprehensive Genomic Profiling Product Portfolio
- 8.17.5 Roche Recent Developments
- 8.18 Guardant Health
- 8.18.1 Guardant Health Company Information
- 8.18.2 Guardant Health Business Overview
- 8.18.3 Guardant Health Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.18.4 Guardant Health Comprehensive Genomic Profiling Product Portfolio
- 8.18.5 Guardant Health Recent Developments
- 8.19 Caris Life Sciences
- 8.19.1 Caris Life Sciences Company Information
- 8.19.2 Caris Life Sciences Business Overview
- 8.19.3 Caris Life Sciences Comprehensive Genomic Profiling Revenue and Gross Margin (2021-2026)
- 8.19.4 Caris Life Sciences Comprehensive Genomic Profiling Product Portfolio
- 8.19.5 Caris Life Sciences Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst